Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, has announced an agreement with Maya health PBC (“Maya”) to help drive brand awareness of the Company’s Psychedelics Genetic Test kit, developed and commercialized by its wholly-owned subsidiary HaluGen Life Sciences Inc. (“HaluGen”).
Maya has developed a measurement-based care platform designed to support psychedelic practitioners and patients. The comprehensive and secure platform was made for psychedelic practitioners, retreat facilitators, ketamine clinicians and integration coaches and enables them to optimize services and scale safely and effectively.
The agreement with Maya is expected to drive awareness and potential sales of HaluGen’s genetic test kit, a first-of-its-kind product launched in the U.S. on June 10 and in Canada on April 6.
The test kit identifies specific DNA biomarkers to gauge the risk and potential of adverse reactions toward hallucinogenic drugs. The test provides users with personalized reports and actionable insight into the short and long-term potential of psychedelic-induced risks, such as psychosis. Maya platform users will be able to fully integrate the use of HaluGen’s test kits as a preparatory measure to better understand a patient’s genetic profile as it relates to preparing for psychedelic-assisted therapies.
“Maya and Entheon share a mutual vision to help create safer psychedelic experiences and help people make informed choices about their treatment. Data and measurement-based information is critical to providing optimal psychedelic healthcare and Maya’s solution is in strong alignment with the types of tools we are developing at Entheon, such as Halugen’s Genetic test kit,” said Entheon Biomedical’s Chief Executive Officer, Timothy Ko. “This is also the third such agreement we’ve been able to formalize in as many weeks and is an indicator of the true value that our test brings to the field, including developers such as Maya. We anticipate as these agreements begin to foment, we will see an increased uptake in these kits, which will ultimately drive growth and revenue.”
“We are excited to partner with Entheon Biomedical as we work together to provide data-based information to practitioners and patients alike, improving treatment protocols and health outcomes,” said Maya CEO and Founder, David Champion. “This shared mission to bring psychedelic treatment into the mainstream will be driven by the integration of tools such as these, that create a greater understanding of the potential for these types of treatment.”
About Entheon Biomedical Corp.
Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective N,N-dimethyltryptamine based psychedelic therapeutic products (“DMT Products”) for the purposes of treating addiction and substance use disorders. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.
About Maya PBC
Maya’s mission is to empower practitioners with the technology and insight they need to scale psychedelic healthcare safely and effectively. Maya is a measurement-based care platform designed to support psychedelic practitioners and patients. Maya is the result of almost two years working with the community, carefully developing the outlines of a platform we believe will empower psychedelic practitioners. Maya is a Colorado Public Benefit Corporation (PBC).
On Behalf of the Board of Directors,
Timothy Ko, CEO
For more information, please contact the Company at:
For media inquiries, please contact Crystal Quast at:
Telephone: +1 (647) 529-6364
Cautionary Note on Forward-Looking Information
This news release includes certain forward-looking statements and forward-looking information (collectively, “forward-looking statements“) within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein including, without limitation, statements with respect to the generation of revenue by the Company and the anticipated business plans and timing of future activities of the Company, are forward-looking statements. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Often, but not always, forward looking information can be identified by words such as “pro forma”, “plans”, “expects”, “will”, “may”, “should”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “potential” or variations of such words including negative variations thereof, and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and other factors include, among others, the Company being able to follow through with anticipated business plans and timing of future activities of the Company, the ability of the Company to obtain sufficient financing to fund its business activities and plans, delays in obtaining regulatory approvals (including of the Canadian Securities Exchange), changes in laws, regulations and policies affecting the Company’s operations and the Company’s limited operating history.
Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update any of the forward-looking statements in this presentation or incorporated by reference herein, except as otherwise required by law.
The Canadian Securities Exchange has not approved nor disapproved the contents of this news release.
Source: Entheon Biomedical Corp.